A Study Assessing Repatha in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease (clinicaltrials.gov) - Sep 4, 2026 - P=N/A | N=7000 | Active, not recruiting | Sponsor: Amgen | Recruiting ➔ Active, not recruiting
Enrollment closed • Real-world evidence • Atherosclerosis • Cardiovascular
|